Sajid Jalil1, James J Grady, Chul Lee, Karl E Anderson. 1. Division of Human Nutrition, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas, USA.
Abstract
BACKGROUND & AIMS: Porphyria cutanea tarda (PCT) is the most common of the human porphyrias and results from an acquired deficiency of hepatic uroporphyrinogen decarboxylase (UROD). Some susceptibility factors have been identified; we examined associations among multiple factors in a large cohort of patients. METHODS: Multiple known or suspected susceptibility factors and demographic and clinical features of 143 patients (mean age 52 years, 66% male, 88% Caucasian) with documented PCT (mean onset at 41 +/- 8.8 years) were tabulated; associations were examined by contingency tables, classification and regression tree (CART) analysis, and logistic regression. RESULTS: The most common susceptibility factors for PCT were ethanol use (87%), smoking (81%), chronic hepatitis C virus (HCV) infection (69%), and HFE mutations (53%; 6% C282Y/C282Y and 8% C282Y/H63D). Of those who underwent hepatic biopsy or ultrasound, 56% had evidence of hepatic steatosis. Of those with PCT, 66% of females took estrogen, 8% were diabetic, 13% had human immunodeficiency virus (HIV) infection, and 17% had inherited uroporphyrinogen decarboxylase (UROD) deficiency (determined by low erythrocyte UROD activity). Three or more susceptibility factors were identified in 70% of patients. HCV infection in patients with PCT was significantly associated with other behavior-related factors such as ethanol use (odds ratio [OR], 6.3) and smoking (OR, 11.9). CONCLUSIONS: Susceptibility factors for PCT were similar to previous studies; most patients had 3 or more susceptibility factors. Associations between PCT and HCV, ethanol or smoking could be accounted for by a history of multiple substance abuse; other factors are distributed more randomly among patients. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS:Porphyria cutanea tarda (PCT) is the most common of the human porphyrias and results from an acquired deficiency of hepaticuroporphyrinogen decarboxylase (UROD). Some susceptibility factors have been identified; we examined associations among multiple factors in a large cohort of patients. METHODS: Multiple known or suspected susceptibility factors and demographic and clinical features of 143 patients (mean age 52 years, 66% male, 88% Caucasian) with documented PCT (mean onset at 41 +/- 8.8 years) were tabulated; associations were examined by contingency tables, classification and regression tree (CART) analysis, and logistic regression. RESULTS: The most common susceptibility factors for PCT were ethanol use (87%), smoking (81%), chronic hepatitis C virus (HCV) infection (69%), and HFE mutations (53%; 6% C282Y/C282Y and 8% C282Y/H63D). Of those who underwent hepatic biopsy or ultrasound, 56% had evidence of hepatic steatosis. Of those with PCT, 66% of females took estrogen, 8% were diabetic, 13% had humanimmunodeficiency virus (HIV) infection, and 17% had inherited uroporphyrinogen decarboxylase(UROD) deficiency (determined by low erythrocyte UROD activity). Three or more susceptibility factors were identified in 70% of patients. HCV infection in patients with PCT was significantly associated with other behavior-related factors such as ethanol use (odds ratio [OR], 6.3) and smoking (OR, 11.9). CONCLUSIONS: Susceptibility factors for PCT were similar to previous studies; most patients had 3 or more susceptibility factors. Associations between PCT and HCV, ethanol or smoking could be accounted for by a history of multiple substance abuse; other factors are distributed more randomly among patients. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: K K Steinberg; M E Cogswell; J C Chang; S P Caudill; G M McQuillan; B A Bowman; L M Grummer-Strawn; E J Sampson; M J Khoury; M L Gallagher Journal: JAMA Date: 2001-05-02 Impact factor: 56.272
Authors: A L Martinelli; M A Zago; A M Roselino; A B Filho; M G Villanova; M Secaf; M H Tavella; L N Ramalho; S Zucoloto; R F Franco Journal: Am J Gastroenterol Date: 2000-12 Impact factor: 10.864
Authors: Z J Bulaj; J D Phillips; R S Ajioka; M R Franklin; L M Griffen; D J Guinee; C Q Edwards; J P Kushner Journal: Blood Date: 2000-03-01 Impact factor: 22.113
Authors: A Tannapfel; U Stölzel; E Köstler; S Melz; M Richter; V Keim; D Schuppan; C Wittekind Journal: Virchows Arch Date: 2001-07 Impact factor: 4.064
Authors: A G Smith; B Clothier; P Carthew; N L Childs; P R Sinclair; D W Nebert; T P Dalton Journal: Toxicol Appl Pharmacol Date: 2001-06-01 Impact factor: 4.219
Authors: Norman G Egger; Douglas E Goeger; Deborah A Payne; Emil P Miskovsky; Steven A Weinman; Karl E Anderson Journal: Dig Dis Sci Date: 2002-02 Impact factor: 3.199
Authors: John D Phillips; Hector A Bergonia; Christopher A Reilly; Michael R Franklin; James P Kushner Journal: Proc Natl Acad Sci U S A Date: 2007-03-09 Impact factor: 11.205
Authors: Jeffrey K Wickliffe; Sherif Z Abdel-Rahman; Chul Lee; Csilla Kormos-Hallberg; Gagan Sood; Catherine M Rondelli; James J Grady; Robert J Desnick; Karl E Anderson Journal: Mol Med Date: 2010-10-15 Impact factor: 6.354
Authors: Ashwani K Singal; Krishna V R Venkata; Sarat Jampana; Fakhar-Ul Islam; Karl E Anderson Journal: Am J Med Sci Date: 2017-03-08 Impact factor: 2.378
Authors: Ashwani K Singal; Csilla Kormos-Hallberg; Chul Lee; Vaithamanithi M Sadagoparamanujam; James J Grady; Daniel H Freeman; Karl E Anderson Journal: Clin Gastroenterol Hepatol Date: 2012-09-14 Impact factor: 11.382